

Barcelona, Spain
September 16, 2021

Almirall announces pricing of €300 Million in the issuance of senior notes due 2026

- “Standard & Poor’s” and “Moody’s” have issued their respective ratings with regard to the notes: “Moody’s” has assigned Ba3 rating to Almirall’s senior notes while “Standard & Poor’s” assigned BB- rating
- The Notes will bear an annual interest of 2.125%, payable semi-annually

BARCELONA, Spain. September 16, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announces that it has successfully completed the pricing of the issuance of senior notes in an aggregate principal amount of €300 million due 2026. The Notes are offered only to qualified institutional buyers, in accordance with Rule 144A under the United States Securities Act of 1933, as amended (the “Securities Act”), and to non-US persons outside the United States in accordance with Regulation S under the Securities Act.

The Notes will bear an annual interest of 2.125%, payable semi-annually. The closing of the issuance and payment of the Notes is expected to take place on or about September 22, 2021, subject to compliance with certain conditions precedent customary for transactions of this nature.

The proceeds from the issuance of the Notes will be used: (i) at their maturity, to repay in full and cancel the Company’s €250,000,000 aggregate principal amount of 0.250% senior unsecured conditionally convertible bonds due December 14, 2021, including accrued and unpaid interest; (ii) to pay transaction fees and expenses; and (iii) for general corporate purposes.

The pharmaceutical company also announced that the agencies “Standard & Poor’s” and “Moody’s” have issued their respective ratings with regard to the issuer entity, Almirall, and the Notes. “Standard & Poor’s” has assigned corporate rating (BB-) and Notes rating (BB-); and “Moody’s” has assigned corporate rating (Ba3) and Notes rating (Ba3).

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit [almirall.com](https://www.almirall.com)

Media contact:**Tinkle**

Pilar Colomer

pcolomer@tinkle.es

Phone: (+34) 93 545 12 51

Investors' Relations contact**Almirall**

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone: (+34) 93 291 3087

Corporate Communications contact:**Almirall**

Maria Duro

maria.duro@almirall.com

Phone: (+34) 671 580 492

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.